The INS requires abstract authors to give a balanced view of therapeutic options, and encourages the use of generic names in place of product trade names. Abstracts that are promotional in nature will not be accepted. To help ensure commercial independence, abstract authors are respectfully asked to adhere to the following guidelines:

1. If a product and/or company name is needed to identify a device used in a study, then they should appear ONLY in the Methods and Materials section.
2. Product names (in the Methods and Materials section) should be followed by the company name, city, state, country. Products should bear their trademarks.
3. Abstracts must not contain any company logos nor commercial messaging. Institution or hospital logos are allowed.
4. Submitters of any abstract who do not comply with the above will be requested to make edits to their abstracts and failing to do so will result in the abstract being removed from the program.
5. The scientific oversight committee will review all abstracts and any changes they request due to ethical or commercial bias concerns must be implemented.
6. Presenting/Main authors who are identified as potentially having a relevant conflict of interest will be requested to complete a Resolution of Conflict of Interest (COI) form, in addition to the COI disclosure forms they complete as part of the system.

Note: Industry employees’ participation as presenters in the scientific program is only allowed if they agree to speak only on completely non-commercial topics, unrelated to any of their company’s products, such as:

•  basic science research (e.g. pre-clinical research, or therapy discovery)
•  process or methodologies of research unrelated to a specific disease or device
•  mechanisms of action unrelated to a specific product